These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Elevated thyroxine levels in a euthyroid patient. A search for the cause of euthyroid hyperthyroxinemia. Uy HL; Reasner CA Postgrad Med; 1994 Oct; 96(5):195-202. PubMed ID: 7937417 [TBL] [Abstract][Full Text] [Related]
63. [Erythrocyte carbonic anhydrase I and zinc concentrations in thyrotoxicosis reflect integrated thyroid hormone levels over the previous few months]. Yoshida K Rinsho Byori; 2007 Jun; 55(6):560-5. PubMed ID: 17657991 [TBL] [Abstract][Full Text] [Related]
64. [The management of thyrotoxicosis: a schematic approach]. Papi G; Carapezzi C; Corsello SM Minerva Endocrinol; 2002 Jun; 27(2):119-26. PubMed ID: 11961503 [TBL] [Abstract][Full Text] [Related]
65. [Cardiovascular manifestations of thyrotoxicosis and thyroid dysfunction caused by amiodarone]. Simkó J; Barta K; Szabó Z; Varga E; Nagy E; Lorincz I Orv Hetil; 2004 Nov; 145(48):2411-7. PubMed ID: 15638034 [TBL] [Abstract][Full Text] [Related]
66. When and how to follow patients after treatment for hyper- and hypothyroidism? Beckers C J Endocrinol Invest; 1986; 9 Suppl 4():89-93. PubMed ID: 3549857 [No Abstract] [Full Text] [Related]
67. Hypokalaemic periodic paralysis associated with thyrotoxicosis. Agarwal AK; Wadhwa S; Wali M J Indian Med Assoc; 1995 Sep; 93(9):359-60, 358. PubMed ID: 8648161 [No Abstract] [Full Text] [Related]